Drug Trial Radar · NCT05225805
Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis
Last checked: Nov 19, 2026Latest source record: Jun 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Mar 1, 2022
Primary completion
Sep 20, 2022
Study completion Jan 13, 2023
Sponsor
- Lead sponsor
- Nabriva Therapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Feb 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is intended to assess the pharmacokinetic (PK) and safety of a single dose of IV and oral formulations of lefamulin in adults with cystic fibrosis (CF).
Conditions
- Cystic Fibrosis
Interventions
LefamulinDrug
Antibiotic
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Median for Lefamulin and Its Main Metabolite BC-8041 for PK Plasma Parameter Tmax in Cystic Fibrosis (CF) Patients.Time frame: Pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 2 hrs, 4 hrs, 8 hrs, 12 hrs & 24 hrs Post-dose
- The Key Geometric Mean for Lefamulin and Its Main Metabolite BC-8041 for PK Plasma Parameter Cmax in CF Patients.Time frame: Pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 2 hrs, 4 hrs, 8 hrs, 12 hrs & 24 hrs Post-dose
- The Key Geometric Mean for Lefamulin and Its Main Metabolite BC-8041 for PK Plasma Parameter AUC(0-last) in CF Patients.Time frame: Pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 2 hrs, 4 hrs, 8 hrs, 12 hrs & 24 hrs Post-dose
- The Key Geometric Mean for Lefamulin and Its Main Metabolite BC-8041 for PK Plasma Parameter AUC(0-inf) in CF Patients.Time frame: Pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 2 hrs, 4 hrs, 8 hrs, 12 hrs & 24 hrs Post-dose
- The Key Geometric Mean for Lefamulin and Its Main Metabolite BC-8041 for PK Plasma Parameter t1/2 in CF Patients.Time frame: Pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 2 hrs, 4 hrs, 8 hrs, 12 hrs & 24 hrs Post-dose
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of Kansas School of Medicine
Kansas City, Kansas
Boston Children's Hospital
Boston, Massachusetts
New York Medical College
Valhalla, New York
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Penn State University College of Medicine
Hershey, Pennsylvania
University of Utah
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.